Other immune checkpoint blocking antibodies also elicit anti-tumor activity, exemplified by anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4), which is less widely used due to its toxic side effects. The gene discussed is CTLA4; the disease is neoplasm.